



May 21th,2009

PRESS RELEASE

Zeria Pharmaceutical Co., Ltd.
10-11 Nihonbashi-Kobunacho,
Chuo-ku, Tokyo 103-8351

Approval of "Promac® granules 15%", Zinc Containing Anti-gastric Ulcer Agent, in Korea

Tokyo, Japan (May 21th, 2009): Zeria Pharmaceutical Co.,Ltd. (Zeria) announced that SK Chemicals (headquarters: Seoul; CEO: Chang-Keun Kim) has received the marketing approval of "Promac® granules 15%" (Polaprezinc) , Zeria out-lisensed zinc containing anti-gastric ulcer agent, for the indication of gastritis and the gastric ulcer from the Korea Food & Drug Administration on April 13, 2009.

Polaprezinc is a chelate complex of essential trace element zinc and endogenous peptide L-carnosine abounding in the vertebrate muscle, and has various actions such as wound healing facilitation, anti-inflammation and anti-oxidation. Polaprezinc exerts therapeutic effects on gastric ulcer through adhesion and permeation specifically at damaged gastric mucosa and active repair of the damaged as well as direct protection through an anti-oxidation, a membrane stabilization and heat shock protein induction.

Zeria received marketing approval of "Promac® granules 15%", and has sold it in Japan since October, 1994. In July, 2006, an additional formulation "Promac® D tablets 75" was launched as the first orally disintegrating tablet of cytoprotective anti-ulcer agent in Japan in order to improve patient compliance. To maximize the product value, Zeria conducts a phase III trial for taste disorder as an additional indication in Japan..

SK Chemicals is going to establish its own presence in the gastrointestinal field based on the marketing and sales of Promac® in addition to Levopride® (levosulpiride) and Omed® (omeprazole). The market size of cytoprotective agents in Korea is 148.9 billion won in 2008 (IMS Health Korea), an increase of 12.4% in comparison with previous year, and its continuous growth in coming years is expected, due to increasing number of patients suffering from gastritis and gastric ulcer.

About SK Chemicals

SK Chemicals is an affiliate company of SK group, one of the top 3 groups in Korea, and expands Green Chemicals Business (eco-friendly chemistry) and Life Sciences Business (total health care), etc., employing 1,543 people with 2008 sales of 1,086 billion won.

The Life Science business, one of the core businesses of SK Chemicals, focuses on the therapeutic field of cardiovascular, orthopedics, gastrointestinal, vaccines, and blood derivatives, and is aiming to be a total health company including synthetic new drugs, bio medicines, medical devices and medical services